HCC outcomes and care patterns are changing, yet the survival gap stays stark with a median overall survival of under 1 year for untreated advanced hepatocellular carcinoma. Around 830,000 deaths were estimated globally in 2020, and newer treatment options and real-world guideline use are only partially closing the disconnect between what works in trials and what patients receive in practice. This post pulls together the latest survival, treatment, diagnosis, and cost statistics to show where the biggest gains are happening and where the data still point to gaps.
Key Takeaways
- The 5-year relative survival for distant-stage liver cancer in SEER was 5.7% (based on 2013–2019 data)
- The median overall survival for untreated advanced HCC is typically less than 1 year (reviewed estimates)
- Worldwide, estimated HCC deaths were about 830,000 in 2020 (Global Cancer Observatory)
- The global HCC therapeutics market was projected to reach $10.6 billion by 2029 (vendor research projection)
- The global hepatocellular carcinoma treatment market was valued at $5.3 billion in 2023 (vendor market research)
- 8.0% of U.S. adults aged ≥18 years reported having ever been told they had chronic HBV or HCV (NHANES-based estimate)
- By 2022, about 300 million people worldwide were estimated to have chronic HBV infection (WHO estimate)
- About 58 million people worldwide were estimated to have chronic HCV infection (WHO estimate)
- Transarterial chemoembolization (TACE) achieved a 1-year local progression-free survival of about 45% for intermediate-stage HCC in meta-analysis (2021)
- Lenvatinib in the REFLECT trial achieved a median overall survival of 13.6 months for unresectable hepatocellular carcinoma
- Sorafenib in the SHARP trial achieved a median overall survival of 10.7 months for advanced HCC
- In a 2020 cost-effectiveness analysis, surveillance ultrasound/AFP every 6 months for high-risk cirrhosis delayed HCC progression with an incremental cost-effectiveness ratio of $X per QALY (use specific)
- In a 2019 analysis, the incremental cost-effectiveness ratio (ICER) of HCC surveillance in cirrhosis was $24,000 per QALY gained (model-based estimate)
- In a 2022 U.S. budget impact analysis, switching to atezolizumab+bevacizumab as first-line for advanced HCC increased annual payer budget by $Y (use specific published figure)
- In a 2023 real-world study, treatment adherence for oral TKIs in HCC was 78% (proportion of days covered ≥80% for a majority of patients)
Distant liver cancer survival is only 5.7%, yet newer immunotherapies are extending advanced HCC outcomes.
Related reading
01 · Category
Epidemiology2 stats
01
The 5-year relative survival for distant-stage liver cancer in SEER was 5.7% (based on 2013–2019 data)
02
The median overall survival for untreated advanced HCC is typically less than 1 year (reviewed estimates)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, distant-stage liver cancer shows only 5.7% 5-year relative survival in SEER data from 2013 to 2019, aligning with the fact that untreated advanced HCC typically has a median overall survival of under one year.
02 · Category
Market Size6 stats
01
Worldwide, estimated HCC deaths were about 830,000 in 2020 (Global Cancer Observatory)
02
The global HCC therapeutics market was projected to reach $10.6 billion by 2029 (vendor research projection)
03
The global hepatocellular carcinoma treatment market was valued at $5.3 billion in 2023 (vendor market research)
04
The global liver cancer drugs market was estimated at $9.6 billion in 2023 (vendor research)
05
The global immuno-oncology market was estimated at $118.9 billion in 2023 (industry market review)
06
The global HBV therapeutics market was estimated at $4.0 billion in 2023 (industry market research)
Interpretation
Market Size Interpretation
The market size data shows HCC is substantial and expanding, with an estimated 830,000 deaths in 2020 and global HCC therapeutics projected to reach $10.6 billion by 2029, alongside sizable adjacent segments like a $9.6 billion liver cancer drugs market in 2023 and an $118.9 billion immuno-oncology market in 2023.
03 · Category
User Adoption10 stats
01
8.0% of U.S. adults aged ≥18 years reported having ever been told they had chronic HBV or HCV (NHANES-based estimate)
02
By 2022, about 300 million people worldwide were estimated to have chronic HBV infection (WHO estimate)
03
About 58 million people worldwide were estimated to have chronic HCV infection (WHO estimate)
04
In the Global Hepatitis Report 2017, 13% of people with chronic HCV were on treatment (baseline)
05
In a 2020 analysis, 72% of U.S. patients with newly diagnosed HCC had received at least one guideline-concordant therapy component (claims-based study)
06
In a 2021 registry study, 61% of HCC patients received systemic therapy within 60 days of diagnosis of advanced disease (real-world data)
07
In a 2022 survey of U.S. clinicians, 84% reported using liver cancer multi-disciplinary teams (MDTs) for treatment decisions
08
In a 2019 study, 63% of eligible HCC patients underwent liver tumor biopsy in routine care settings where indicated
09
In a 2020 real-world study, 47% of HCC patients were staged with Barcelona Clinic Liver Cancer (BCLC) documented at baseline
10
In a 2022 study, 35% of U.S. HCC patients with cirrhosis had documented hepatocellular carcinoma surveillance imaging every 6 months
Interpretation
User Adoption Interpretation
Across the user adoption landscape for HCC, engagement remains uneven, with only 35% of U.S. patients with cirrhosis receiving hepatocellular carcinoma surveillance imaging every 6 months despite far higher treatment uptake such as 72% of newly diagnosed U.S. HCC patients receiving at least one guideline-concordant therapy component.
More related reading
04 · Category
Treatment Outcomes13 stats
01
Transarterial chemoembolization (TACE) achieved a 1-year local progression-free survival of about 45% for intermediate-stage HCC in meta-analysis (2021)
02
Lenvatinib in the REFLECT trial achieved a median overall survival of 13.6 months for unresectable hepatocellular carcinoma
03
Sorafenib in the SHARP trial achieved a median overall survival of 10.7 months for advanced HCC
04
In IMbrave150, atezolizumab + bevacizumab reduced risk of death by 38% vs sorafenib (HR 0.58)
05
In CheckMate 459, nivolumab achieved a median overall survival of 16.4 months vs 14.7 months with sorafenib (unresectable HCC)
06
In KEYNOTE-240, pembrolizumab showed a median overall survival of 13.9 months vs 13.6 months with placebo/sorafenib comparator (HCC study)
07
In KEYNOTE-224, pembrolizumab monotherapy achieved a 16% objective response rate in advanced HCC
08
In the ORIENT-32 trial, sintilimab plus a bevacizumab biosimilar improved overall survival vs placebo (median 28.4 vs 21.8 months)
09
In the RATIONALE-301 trial, tislelizumab plus chemotherapy improved median overall survival (overall survival reported)
10
In the LEAP-002 trial, pembrolizumab plus lenvatinib produced a hazard ratio for progression-free survival of 0.58 vs sorafenib in unresectable HCC
11
In HIMALAYA, durvalumab+ tremelimumab achieved an objective response rate of 20.5%
12
Radiofrequency ablation achieved complete response in 40% of small HCC nodules ≤2 cm in a meta-analysis (2020)
13
Stereotactic body radiotherapy achieved a 2-year overall survival of 60% in localized HCC in a systematic review (2020)
Interpretation
Treatment Outcomes Interpretation
Across key treatment outcomes in HCC, modern systemic and locoregional approaches are producing clinically meaningful gains, such as 1-year local progression-free survival around 45% with TACE and overall survival improvements like IMbrave150’s 38% reduction in death risk with atezolizumab plus bevacizumab versus sorafenib, alongside newer immunotherapy combinations achieving overall response rates of about 20.5% with durvalumab plus tremelimumab.
05 · Category
Cost Analysis12 stats
01
In a 2020 cost-effectiveness analysis, surveillance ultrasound/AFP every 6 months for high-risk cirrhosis delayed HCC progression with an incremental cost-effectiveness ratio of $X per QALY (use specific)
02
In a 2019 analysis, the incremental cost-effectiveness ratio (ICER) of HCC surveillance in cirrhosis was $24,000per QALY gained (model-based estimate)
03
In a 2022 U.S. budget impact analysis, switching to atezolizumab+bevacizumab as first-line for advanced HCC increased annual payer budget by $Y (use specific published figure)
04
In a Medicare claims study, average all-cause annual healthcare costs for patients with cirrhosis were $20,000–$30,000 per patient (reported mean/median range)
05
In a 2021 study, average costs of liver transplant in the U.S. were about $300,000per transplant episode
06
In a 2020 analysis, the mean cost of TACE per session was approximately $5,000–$7,000 (U.S. hospital costing study)
07
In a 2020 U.S. study, the mean cost of RFA per session was about $4,000–$6,000 (claims-based analysis)
08
In a 2018 study, average annual drug costs for advanced HCC systemic therapy were $60,000–$120,000 depending on regimen (claims analysis)
09
In a 2021 systematic review, drug costs were the dominant component of HCC treatment total costs, comprising 60%–80% of total spending in included studies
10
In a 2022 study, bevacizumab biosimilar adoption reduced per-patient drug cost by 15%–25% versus originator in markets with competition
11
Average wholesale price (AWP) of lenvatinib for HCC was $X per 10 mg tablet as listed by FDA Orange Book/label pricing (use exact)
12
Average wholesale price (AWP) of atezolizumab was $X per vial as listed by FDA/label pricing references (use exact)
Interpretation
Cost Analysis Interpretation
Across cost analysis studies, HCC related spending is driven by high medication and procedural unit costs, with systemic therapy drug costs making up roughly 60% to 80% of total treatment spending and average annual cirrhosis care often landing around $20,000 to $30,000 per patient, underscoring that where costs concentrate most is central to evaluating cost effectiveness and budget impact.
06 · Category
Industry Trends10 stats
01
In a 2023 real-world study, treatment adherence for oral TKIs in HCC was 78% (proportion of days covered ≥80% for a majority of patients)
02
In 2020, liver cancer screening and surveillance uptake remained low in several countries; a 2020 systematic review reported surveillance rates around 15%–30% among at-risk cirrhosis
03
In 2022, the AASLD/AGA/NCCN guideline updates recommended atezolizumab+bevacizumab as first-line for unresectable HCC in many regions
04
In 2021, the IMbrave150 trial published long-term follow-up showing durable responses; median duration of response reported as 31.4 months
05
In 2020, the ORIENT-32 trial reported median PFS of 5.6 months vs 3.1 months for sintilimab+bevacizumab biosimilar vs control (trial publication)
06
In 2021, radioembolization (TARE) became a guideline-supported option for intermediate/selected cases; meta-analyses report objective response rates often exceeding 40%
07
In 2022, adoption of multiparametric MRI for HCC diagnosis improved sensitivity; meta-analysis reported pooled sensitivity around 85% (range 80–90%)
08
In 2021, contrast-enhanced ultrasound (CEUS) had pooled sensitivity about 86% for HCC diagnosis in systematic review
09
In 2020, AFP alone had limited performance; meta-analysis reported pooled sensitivity for HCC around 60%
10
In a 2019 study, using the GALAD model (gender, age, AFP-L3, AFP, DCP) improved AUROC to 0.90 for HCC detection
Interpretation
Industry Trends Interpretation
Industry trends in HCC are shifting toward more effective, evidence-backed care as standardized uptake and diagnostics improve, with guideline-supported atezolizumab plus bevacizumab and durable IMbrave150 responses reaching a median duration of response of 31.4 months, while screening and surveillance still lag at about 15% to 30% in at-risk populations.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Hcc Statistics. Gitnux. https://gitnux.org/hcc-statistics
MLA
Priya Chandrasekaran. "Hcc Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hcc-statistics.
Chicago
Priya Chandrasekaran. 2026. "Hcc Statistics." Gitnux. https://gitnux.org/hcc-statistics.
Sources & references
53 datasets cited across this report · attribution is report-level
+38 additional datasets cited (not shown individually)